None listed
Conditions
Interventions
None listed
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: * Target population for conversion analysis 1) Diagnosed with multiple myeloma that meets the diagnostic criteria of the International Myeloma Working Group 2) Previously treated with at least one proteasome inhibitor, one immune modulatory drug, and one anti-CD38 monoclonal antibody, and confirmed to have relapsed/refractory multiple myeloma. 3) Patients who are currently receiving or planning to receive treatment with Teclistamab, or patients who have completed treatment and can be followed up. 4) Cases that can provide the following information - Age, gender, date of diagnosis, previous treatment, Teclistamab administration/discontinuation/end date, dosage, adverse reactions, progression of multiple myeloma, survival, date of death 5) Voluntarily agreed to understand the research content. * Retrospective analysis subjects 1) Diagnosed with multiple myeloma that meets the diagnostic criteria of the International Myeloma Working Group 2) Previously treated with at least one proteasome inhibitor, one immune modulatory drug, and one anti-CD38 monoclonal antibody, and confirmed to have relapsed/refractory multiple myeloma. 3) Patients who received Teclistamab treatment from October 1, 2022, to May 31, 2023, and were lost to follow-up or died after treatment discontinuation. 4) Cases that can provide the following: - Age, gender, date of diagnosis, previous treatments, Teclistamab administration/discontinuation/end date, dosage, adverse reactions, progression of multiple myeloma, survival, date of death
Exclusion criteria
Exclusion criteria: 1) Under 18 years old 2) Active plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome 3) In cases that do not meet the inclusion criteria above
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| duration of response;time to response;progression free survival;overall survival;safety | — |
Countries
Korea, Republic of
Contacts
Public ContactNaEun Lee
Asan Medical Center
Outcome results
None listed